Myeloproliferative neoplasms 5 years after discovery of JAK2V617F: what is the impact of JAK2 inhibitor therapy?
about
Current outlook on molecular pathogenesis and treatment of myeloproliferative neoplasms.Emerging treatments for essential thrombocythemiaJAK2 inhibitors in the treatment of myeloproliferative neoplasms.Emerging drugs for polycythemia vera.JAK inhibition: the key to treating myeloproliferative neoplasm?
P2860
Myeloproliferative neoplasms 5 years after discovery of JAK2V617F: what is the impact of JAK2 inhibitor therapy?
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 23 May 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Myeloproliferative neoplasms 5 ...... act of JAK2 inhibitor therapy?
@en
Myeloproliferative neoplasms 5 ...... act of JAK2 inhibitor therapy?
@nl
type
label
Myeloproliferative neoplasms 5 ...... act of JAK2 inhibitor therapy?
@en
Myeloproliferative neoplasms 5 ...... act of JAK2 inhibitor therapy?
@nl
prefLabel
Myeloproliferative neoplasms 5 ...... act of JAK2 inhibitor therapy?
@en
Myeloproliferative neoplasms 5 ...... act of JAK2 inhibitor therapy?
@nl
P2860
P1433
P1476
Myeloproliferative neoplasms 5 ...... act of JAK2 inhibitor therapy?
@en
P2093
Raoul Tibes
Ruben A Mesa
P2860
P304
P356
10.3109/10428194.2011.566952
P577
2011-05-23T00:00:00Z